AOD-9604 and Tirzepatide are both Metabolic peptides, but they're studied for different things. In short, AOD-9604 is a growth-hormone fragment studied for fat metabolism, while Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for diabetes and weight management. This page compares the two side by side — what each is researched for, how mature the evidence is, and how they're typically used — so you can see where they overlap and where they differ. It's educational information only, not medical advice, and neither is a substitute for a conversation with a licensed professional.
AOD-9604 vs Tirzepatide at a glance
| AOD-9604 | Tirzepatide | |
|---|---|---|
| Category | Metabolic | Metabolic |
| In short | A growth-hormone fragment studied for fat metabolism. | A dual GIP/GLP-1 receptor agonist approved for diabetes and weight management. |
| Researched for | Fat metabolism, Body composition, Cartilage/joint studies | Blood sugar regulation, Weight management, Metabolic health |
| Research status | Human trials for obesity did not meet primary endpoints; further research ongoing. | FDA-approved with large-scale human clinical trials. |
| Typically stacked with | — | — |
| Key consideration | Weight-loss efficacy was not established in clinical trials. Not an approved therapy. | Prescription medication with known side effects. Use only under medical supervision. |
How does AOD-9604 work?
AOD-9604 is a modified fragment of the C-terminus of human growth hormone (residues 176-191). It was designed to stimulate fat metabolism (lipolysis) without the growth-promoting or blood-sugar effects of full-length growth hormone.
How does Tirzepatide work?
Tirzepatide is a "dual agonist" that activates both the GIP and GLP-1 receptors. Engaging two incretin pathways appears to produce strong effects on appetite, blood sugar, and body weight, and it is FDA-approved for type 2 diabetes and chronic weight management.
AOD-9604 vs Tirzepatide: how to choose
Choosing between AOD-9604 and Tirzepatide really comes down to your specific goal — and it's a decision for you and a licensed professional, not something to settle from a web page. AOD-9604 is most associated with Fat metabolism and Body composition, while Tirzepatide leans toward Blood sugar regulation and Weight management. Where they overlap, the practical differences are usually in mechanism and how far the research has actually progressed. Selpho provides no dosing or protocols; if you'd like a research-backed steer for your goals, the free Peptide Advisor is a good starting point.
Frequently asked questions
Both are Metabolic peptides. AOD-9604 is a growth-hormone fragment studied for fat metabolism; Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for diabetes and weight management. They're most researched for Fat metabolism, Body composition (AOD-9604) and Blood sugar regulation, Weight management (Tirzepatide), respectively.
There's no universal "better" — it depends on your goal, and for most of these compounds robust head-to-head human evidence doesn't exist. The right choice is one made with a licensed professional. Selpho does not rank or prescribe; it offers educational information and a research-backed advisor.
They're in the same category, and combining research compounds is something to approach only with a licensed professional, since interactions and individual context matter. Selpho provides no dosing or protocols.
AOD-9604: Human trials for obesity did not meet primary endpoints; further research ongoing. Tirzepatide: FDA-approved with large-scale human clinical trials.
Not sure which fits your goals?
Describe your situation and Selpho's free AI advisor will suggest research-backed peptides — no signup needed.
Try the Peptide AdvisorThis comparison is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.